Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2026)

Stoke Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 35.61% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (down 35.61% YoY), while the FY2025 annual figure was $7.0 million, changed N/A from the prior year.
• Non-Current Deffered Revenue was $6.6 million for Q1 2026 at Stoke Therapeutics, down from $7.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $49.5 million in Q1 2022 to a low of $6.6 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $26.0 million across 5 years, with a median of $29.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue slumped 79.64% in 2024, then rose 3.22% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $36.9 million in 2022, then slipped by 10.26% to $33.1 million in 2023, then sank by 74.93% to $8.3 million in 2024, then slipped by 16.04% to $7.0 million in 2025, then decreased by 5.14% to $6.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $6.6 million (Q1 2026), $7.0 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.